AstraZeneca, AtheroGenics ink $1B licensing deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
AstraZeneca |
AtheroGenics |
$1B licensing deal |
AstraZeneca has rights to AGI-1067, a Phase III drug for the treatment of atherosclerosis, or hardening of the arteries. |
|
Wyeth |
Trubion |
$800M development deal |
The companies have agreed to develop and market antibody-like drugs for inflammatory diseases and cancer. |
|
AstraZeneca |
Targacept |
$300M licensing deal |
The deal is for Targacept's phase II compound, TC-1734, for Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. |
|
Exelixis |
Wyeth |
$157.7M licensing deal |
The deal is for the development of treatments for metabolic and liver disorders. |
|
Trubion |
Wyeth |
$40M collaboration deal |
The two companies will work on developing new treatments for inflammatory diseases and cancer. |
|
DUSA |
Sirius Labs |
$30M buyout |
DUSA will pay $8 million in cash and $17 million in stock, with another $5 million in potential payments for new product launches and sales milestones. |